Described herein are retinoic acid related-related orphan nuclear receptor (ROR) modulators and methods of utilizing ROR-gamma modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R.sup.1, R.sup.2, R.sup.3, and R.sup.4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients. ##STR00001##

The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R.sup.1, R.sup.2, R.sup.3, and R.sup.4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients. ##STR00001##

The present invention relates to a condensed fluorene derivative comprising a hetero ring, and, more specifically, relates to an intermediate for producing a hetero-ring compound able to exhibit the outstanding element characteristic of a long life and outstanding luminance and light-emission efficiency when used as an organic light-emitting material.

The present invention relates to a condensed fluorene derivative comprising a hetero ring, and, more specifically, relates to an intermediate for producing a hetero-ring compound able to exhibit the outstanding element characteristic of a long life and outstanding luminance and light-emission efficiency when used as an organic light-emitting material.

The present invention relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By using the organic electroluminescent compound of the present invention, it is possible to produce an organic electroluminescent device having low driving voltage and excellent luminous efficiency such as current efficiency and power efficiency, emitting color of high purity, and having improved lifespan.

The present invention relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By using the organic electroluminescent compound of the present invention, it is possible to produce an organic electroluminescent device having low driving voltage and excellent luminous efficiency such as current efficiency and power efficiency, emitting color of high purity, and having improved lifespan.

Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts. ##STR00001##

Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts. ##STR00001##

The invention relates to new types of modulators of the cold menthol receptor TRPM8, to methods of modulating the TRPM8 receptor using these modulators; and in particular the use of the modulators for inducing a sensation of coldness; and also the articles and compositions produced using these modulators.